Table 1.
Demographic and clinical characteristics of the study cohort.
| Pembrolizumab group (n = 79) | Nivolumab group (n = 82) | Total (n = 161) | P value | |
|---|---|---|---|---|
| Sex | 0.30 | |||
| Male | 68 (86.1%) | 65 (79.3%) | 133 (82.6%) | |
| Female | 11 (13.9%) | 17 (20.7%) | 28 (17.4%) | |
| Age | 0.046 | |||
| ≥60 | 58 (73.4%) | 47 (57.3%) | 105 (65.2%) | |
| <60 | 21 (26.6%) | 35 (42.7%) | 56 (34.8%) | |
| Median (range) | 64 (32~78) | 61 (27~77) | 63(27-78) | |
| Pathological subtype | 0.174 | |||
| Adenocarcinoma | 33 (41.8%) | 51 (62.2%) | 84 (52.2%) | |
| Squamous carcinoma | 31 (39.2%) | 29 (35.4%) | 60 (37.3%) | |
| Others | 7(8.9%) | 1 (1.2%) | 82 (50.9%) | |
| Unknown | 8 (10.1%) | 1 (1.2%) | 9 (5.6%) | |
| ECOG | 0.056 | |||
| 0 | 4 (5.1%) | 0 (0.0%) | 4 (2.5%) | |
| 1 | 75 (94.9%) | 82 (100%) | 157 (97.5%) | |
| Stage | 0.366 | |||
| III | 17 (21.5%) | 23 (28.1%) | 40 (24.8%) | |
| IV | 62 (78.5%) | 59 (72.0%) | 121 (75.2%) | |
| Smoking status | 0.178 | |||
| Yes | 8 (10.1%) | 15 (18.3%) | 23 (14.3%) | |
| No | 71 (89.9%) | 67 (81.7%) | 138 (85.7%) | |
| Metastatic site | 0.392 | |||
| Bone | 22 (27.9%) | 25 (30.5%) | 47 (29.2%) | |
| Liver | 7 (8.9%) | 9 (11.0%) | 16 (9.9%) | |
| Brain | 12 (15.2%) | 14 (17.1%) | 26 (16.2%) | |
| Adrenal glands | 9 (11.4%) | 3 (3.7%) | 12 (7.5%) | |
| Pleura | 27 (34.2%) | 21 (25.6%) | 48 (29.8%) | |
| Number of metastasis sites | 0.7227 | |||
| 0 | 20 (25.3%) | 23 (28.1%) | 43 (26.7%) | |
| 1 | 41 (51.9%) | 41 (50.0%) | 82 (50.9%) | |
| 2 | 13 (16.5%) | 16 (19.5%) | 29 (18.0%) | |
| 3 | 3 (3.8%) | 2 (2.4%) | 5 (3.1%) | |
| 4 | 2 (2.5%) | 0 (0.0%) | 2 (1.2%) | |
| PD-L1 status | 0.6996 | |||
| <1% | 14 (17.7%) | 11 (13.4%) | 25 (15.5%) | |
| 1%~49% | 10 (12.7%) | 8 (9.8%) | 18 (11.2%) | |
| >50% | 17 (21.5%) | 8 (9.8%) | 25 (15.5%) | |
| Unknown | 38 (48.1%) | 55 (67.1%) | 93 (57.8%) | |
| Radiation therapy | 0.0514 | |||
| Yes | 11 (13.9%) | 22 (26.8%) | 33 (20.5%) | |
| No | 68 (86.1%) | 60 (73.2%) | 128 (79.5%) | |
| Treatment regimen | < 0.001 | |||
| Immune monotherapy | 13 (16.46%) | 66 (80.5%) | 79 (49.1%) | |
| Immune and chemotherapy | 64 (81.01%) | 5 (6.1%) | 69 (42.9%) | |
| Immune and anti-vascular | 2 (2.53%) | 1 (1.2%) | 3 (1.9%) | |
| Immune and immune | 0 (0.00%) | 10 (12.2%) | 10 (6.2%) | |
| Treatment line | < 0.001 | |||
| 1st | 79 (100%) | 0 (0.0%) | 79 (49.1%) | |
| ≥2nd | 0 (0.00%) | 82 (100.0%) | 82 (50.9%) |
ECOG PS, Eastern Cooperative Oncology Group performance- status; PD-L1 TPS, programmed death-1 tumor proportion score.